• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Illumina launches new business to accelerate technology and data-driven discovery

    10/1/25 9:05:00 AM ET
    $ILMN
    Medical Specialities
    Health Care
    Get the next $ILMN alert in real time by email

    New business focuses on developing data assets, software, and AI to fuel life science breakthroughs

    Expands pharma access to large omics datasets to advance target discovery and drug development

    SAN DIEGO, Oct. 1, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) today announced the launch of BioInsight, a new business within Illumina, developed to meet industry demand for deeper biologic insights driven by the need of researchers and pharma companies to access and interpret ever larger-scale multiomic data. By bringing together Illumina's strengths across sequencing, data analysis, software and AI, BioInsight will empower customers and partners with solutions to identify drug targets, understand biological pathways, discover novel disease mechanisms, and build the next wave of biological insights. This move reflects Illumina's commitment to delivering innovative solutions to advance science and health care, and fuels the company's long-term, sustainable growth.

    BioInsight, a new business within Illumina, is launched with a dedicated focus on developing data assets, software, and AI solutions to fuel breakthroughs in life sciences.

    BioInsight will be led by Rami Mehio as senior vice president and general manager. Mehio has led Illumina's Global Software & Informatics team for four years and now joins the company's executive leadership team.

    "Working together with our customers, we are going beyond sequencing and breaking the barrier between omics data generation and transformative insights," said Jacob Thaysen, chief executive officer of Illumina. "BioInsight, under Rami's guidance, will strengthen Illumina's leadership at the intersection of sequencing, software, and AI, with a focus on supporting pharma in drug target discovery and development."

    BioInsight key focus areas:

    • Working with large national initiatives and industry partners to enable large-scale genetic and biological data generation projects.
    • Developing software solutions to analyze multimodal data at population scale.
    • Providing platforms to enable private and secure data access for research and pharmaceutical partners.
    • Developing AI tools through strategic partnerships to build an ecosystem for large-scale multimodal data analysis.

    "We are at a pivotal moment in science and technology," Mehio said. "The dramatic reduction in sequencing costs has unlocked the ability to generate multiomic data at an unprecedented scale. At the same time, we are witnessing an extraordinary rise in AI capabilities. The confluence of these two forces is transforming how we derive biological insights, and Illumina is committed to partnering with our customers and collaborators to develop the largest, highest-quality datasets and the AI-driven tools that turn this data into meaningful discoveries."

    The role of AI, informatics, and insights in life science innovation

    Progress in the life sciences is accelerating as researchers gain the ability to collect and interpret vast amounts of multiomic data. Today, the field is generating more data than ever before, and advanced AI and software are vital to deriving actionable insights from complex multimodal datasets. Ultimately, these insights hold the power to accelerate drug target discovery, disease diagnosis, and therapeutic development. Illumina is organizing its new business to support essential functions that make this possible.

    Multimodal data generation and aggregation - BioInsight will support data generation in three main ways: enabling large national research initiatives, working with corporate partners to develop valuable data assets, and facilitating large-scale federated data networks. This includes expanding beyond traditional genomics to include multiomic and advanced biological data types, such as perturb-seq.

    AI and tool development - BioInsight is designed to harness all available multimodal data, creating the tools and resources needed to help customers and partners achieve meaningful results faster. With these tools, scientists can more quickly identify patterns, discover new drug targets, and improve disease diagnosis and treatment. In addition to developing its own tools and models, Illumina looks to partner with industry leaders to enable a broad ecosystem of tools to be developed leveraging its data assets.

    With intent focus on the growth of scalable data and AI solutions, BioInsight and Illumina will drive customer access to rich omics data insights, faster and more efficiently, to accelerate transformative research and discovery.

    Use of forward-looking statements

    This release may contain forward-looking statements that involve risks and uncertainties. Among the important factors to which our business is subject that could cause actual results to differ materially from those in any forward-looking statements are: (i) challenges inherent in researching, developing and launching new technologies; (ii) our and our partners' ability to deploy new products, services, and applications, and to expand the markets for genomics-related products and services; and (iii) the challenges associated with multiparty collaborations, including our reliance on the performance of such partners, together with other factors detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We undertake no obligation, and do not intend, to update these forward-looking statements, to review or confirm analysts' expectations, or to provide interim reports or updates on the progress of the current quarter.

    About Illumina

    Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with us on X, Facebook, LinkedIn, Instagram, TikTok, and YouTube.

    Contacts

    Investors:

    Illumina Investor Relations

    858-291-6421

    [email protected]

    Media:

    Christine Douglass

    [email protected]

    Rami Mehio, Senior Vice President and General Manager, BioSight at Illumina.

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/illumina-launches-new-business-to-accelerate-technology-and-data-driven-discovery-302572395.html

    SOURCE Illumina, Inc.

    Get the next $ILMN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ILMN

    DatePrice TargetRatingAnalyst
    8/12/2025$94.00Outperform → Neutral
    Daiwa Securities
    7/11/2025$125.00Sector Outperform → Sector Perform
    Scotiabank
    3/4/2025$130.00 → $90.00Neutral
    Citigroup
    2/28/2025$100.00Buy → Hold
    HSBC Securities
    2/10/2025$130.00 → $100.00Equal Weight → Underweight
    Barclays
    2/7/2025$177.00 → $140.00Buy → Hold
    TD Cowen
    12/11/2024$190.00 → $165.00Buy → Neutral
    Citigroup
    11/12/2024$156.00Equal-Weight
    Morgan Stanley
    More analyst ratings

    $ILMN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Illumina launches new business to accelerate technology and data-driven discovery

    New business focuses on developing data assets, software, and AI to fuel life science breakthroughs Expands pharma access to large omics datasets to advance target discovery and drug development SAN DIEGO, Oct. 1, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) today announced the launch of BioInsight, a new business within Illumina, developed to meet industry demand for deeper biologic insights driven by the need of researchers and pharma companies to access and interpret ever larger-scale multiomic data. By bringing together Illumina's strengths across sequencing, data analysis, software and AI, BioInsight will empower customers and partners with solutions to identify drug targets, under

    10/1/25 9:05:00 AM ET
    $ILMN
    Medical Specialities
    Health Care

    Predicta Biosciences Secures $23.4M to Scale its Novel Diagnostic and Analytics Platform for Blood Cancers and Autoimmune Diseases

    Brian McKernan joins as CEO to further advance Predicta's clinical impact, including its non-invasive diagnostic for Multiple Myeloma Predicta Biosciences, a precision oncology company developing novel diagnostic and therapeutic discovery solutions, today announced it has raised an oversubscribed $23.4 million Series A led by Engine Ventures. Additional participating investors include Illumina Ventures, Lightchain Capital, Mass General Brigham Ventures, ACS BrightEdge, Binney Street Capital of Dana-Farber Cancer Institute and Myeloma Solutions Fund. The capital will be used to expand Predicta's team and CLIA-approved lab infrastructure, and advance commercialization of the company's first

    10/1/25 9:00:00 AM ET
    $ILMN
    Medical Specialities
    Health Care

    Illumina advances personalized cancer care with new pharma development partnerships

    Illumina and pharma partners will develop companion diagnostics for historically important KRAS biomarker SAN DIEGO, Sept. 23, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ:ILMN) will partner with multiple global pharmaceutical companies to develop companion diagnostics (CDx) enabled on the TruSight™ Oncology (TSO) Comprehensive genomic profiling test. The continued expansion of tumor-agnostic CDx claims underscores Illumina's commitment to advance access for patients to precision oncology care by generating standardized, globally distributable tests. The new companion diagnostic partnerships will focus on KRAS alterations, which are known to cause uncontrolled cell growth, leading to cancer.

    9/23/25 9:15:00 AM ET
    $ILMN
    Medical Specialities
    Health Care

    $ILMN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP, Chief Technology Officer Barnard Steven covered exercise/tax liability with 287 shares, decreasing direct ownership by 0.85% to 33,546 units (SEC Form 4)

    4 - ILLUMINA, INC. (0001110803) (Issuer)

    9/9/25 7:01:47 PM ET
    $ILMN
    Medical Specialities
    Health Care

    SVP, Chief Commercial Officer Cunningham Everett covered exercise/tax liability with 4,248 shares, decreasing direct ownership by 9% to 41,942 units (SEC Form 4)

    4 - ILLUMINA, INC. (0001110803) (Issuer)

    7/8/25 5:59:00 PM ET
    $ILMN
    Medical Specialities
    Health Care

    Director Ullem Scott B. was granted 307 shares, increasing direct ownership by 4% to 8,137 units (SEC Form 4)

    4 - ILLUMINA, INC. (0001110803) (Issuer)

    7/2/25 4:26:43 PM ET
    $ILMN
    Medical Specialities
    Health Care

    $ILMN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP, Chief Financial Officer Dhingra Ankur bought $495,381 worth of shares (6,100 units at $81.21), increasing direct ownership by 32% to 24,906 units (SEC Form 4)

    4 - ILLUMINA, INC. (0001110803) (Issuer)

    5/14/25 4:20:13 PM ET
    $ILMN
    Medical Specialities
    Health Care

    Chief Executive Officer Thaysen Jacob bought $998,674 worth of shares (12,350 units at $80.86), increasing direct ownership by 17% to 83,390 units (SEC Form 4)

    4 - ILLUMINA, INC. (0001110803) (Issuer)

    5/14/25 4:18:28 PM ET
    $ILMN
    Medical Specialities
    Health Care

    Thaysen Jacob bought $991,672 worth of shares (7,330 units at $135.29), increasing direct ownership by 97% to 14,861 units (SEC Form 4)

    4 - ILLUMINA, INC. (0001110803) (Issuer)

    2/26/24 8:57:29 AM ET
    $ILMN
    Medical Specialities
    Health Care

    $ILMN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Illumina downgraded by Daiwa Securities with a new price target

    Daiwa Securities downgraded Illumina from Outperform to Neutral and set a new price target of $94.00

    8/12/25 7:55:50 AM ET
    $ILMN
    Medical Specialities
    Health Care

    Illumina downgraded by Scotiabank with a new price target

    Scotiabank downgraded Illumina from Sector Outperform to Sector Perform and set a new price target of $125.00

    7/11/25 8:11:04 AM ET
    $ILMN
    Medical Specialities
    Health Care

    Citigroup reiterated coverage on Illumina with a new price target

    Citigroup reiterated coverage of Illumina with a rating of Neutral and set a new price target of $90.00 from $130.00 previously

    3/4/25 8:10:42 AM ET
    $ILMN
    Medical Specialities
    Health Care

    $ILMN
    SEC Filings

    View All

    SEC Form 10-Q filed by Illumina Inc.

    10-Q - ILLUMINA, INC. (0001110803) (Filer)

    8/1/25 5:24:43 PM ET
    $ILMN
    Medical Specialities
    Health Care

    Illumina Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - ILLUMINA, INC. (0001110803) (Filer)

    7/31/25 4:11:41 PM ET
    $ILMN
    Medical Specialities
    Health Care

    SEC Form 8-K filed by Illumina Inc.

    8-K - ILLUMINA, INC. (0001110803) (Filer)

    6/23/25 9:24:49 AM ET
    $ILMN
    Medical Specialities
    Health Care

    $ILMN
    Financials

    Live finance-specific insights

    View All

    Illumina Reports Financial Results for Second Quarter of Fiscal Year 2025

    Revenue of $1.06 billion for Q2 2025, down 3% from Q2 2024 on both a reported and constant currency basisGAAP operating margin of 20.2% and non-GAAP operating margin of 23.8% for Q2 2025GAAP diluted EPS of $1.49 and non-GAAP diluted EPS of $1.19 for Q2 2025Cash provided by operations of $234 million and free cash flow of $204 million for Q2 2025For fiscal year 2025, we now expect:Total company constant currency revenue decline in the range of (2.5%) to (0.5%), up from (3%) to (1%) previouslyNon-GAAP operating margin of approximately 22% - 22.5%, up from 21.5% - 22.0% previouslyNon-GAAP diluted EPS in the range of $4.45 - $4.55, an increase from our May guidance of $4.20 - $4.30. This include

    7/31/25 4:05:00 PM ET
    $ILMN
    Medical Specialities
    Health Care

    Illumina to Announce Second Quarter 2025 Financial Results on Thursday, July 31, 2025

    SAN DIEGO, July 10, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) announced today that it will issue results for the second quarter 2025 following the close of market on Thursday, July 31, 2025. On the same day, at 1:30 pm Pacific Time (4:30 pm Eastern Time) Jacob Thaysen, PhD, Chief Executive Officer, and Ankur Dhingra, Chief Financial Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results. Conference Call Details The conference call will begin at 1:30 pm Pacific Time (4:30 pm Eastern Time) on Thursday, July 31, 2025. Interested parties may access the live webcast via the Investor Info section of Illumina's

    7/10/25 4:05:00 PM ET
    $ILMN
    Medical Specialities
    Health Care

    Infinity Bio Closes $8M Series A Financing Led by Illumina Ventures to Expand Leadership in Antibody Reactome Profiling

    Investment supports platform innovation, commercial scaling, and new service development; Infinity acquires the assets of Serimmune, Inc. Infinity Bio, a biotechnology company pioneering technologies to map immune responses at scale, today announced the successful closing of an $8 million Series A financing round. The round was led by Illumina Ventures, with participation from PTX Capital, Blackbird BioVentures, and Propel Baltimore Fund. As part of the strategic plan to broaden its suite of service offerings, Infinity Bio has acquired the assets of Serimmune, Inc., which was founded in 2014 to provide unbiased antibody reactome services. New MIPSA™ service offerings, including EnviroSI

    6/18/25 9:00:00 AM ET
    $ILMN
    Medical Specialities
    Health Care

    $ILMN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Illumina Inc.

    SC 13G/A - ILLUMINA, INC. (0001110803) (Subject)

    12/6/24 10:11:24 AM ET
    $ILMN
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by Illumina Inc.

    SC 13G - ILLUMINA, INC. (0001110803) (Subject)

    12/5/24 7:27:01 PM ET
    $ILMN
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by Illumina Inc.

    SC 13G/A - ILLUMINA, INC. (0001110803) (Subject)

    11/12/24 3:59:44 PM ET
    $ILMN
    Medical Specialities
    Health Care

    $ILMN
    Leadership Updates

    Live Leadership Updates

    View All

    Predicta Biosciences Secures $23.4M to Scale its Novel Diagnostic and Analytics Platform for Blood Cancers and Autoimmune Diseases

    Brian McKernan joins as CEO to further advance Predicta's clinical impact, including its non-invasive diagnostic for Multiple Myeloma Predicta Biosciences, a precision oncology company developing novel diagnostic and therapeutic discovery solutions, today announced it has raised an oversubscribed $23.4 million Series A led by Engine Ventures. Additional participating investors include Illumina Ventures, Lightchain Capital, Mass General Brigham Ventures, ACS BrightEdge, Binney Street Capital of Dana-Farber Cancer Institute and Myeloma Solutions Fund. The capital will be used to expand Predicta's team and CLIA-approved lab infrastructure, and advance commercialization of the company's first

    10/1/25 9:00:00 AM ET
    $ILMN
    Medical Specialities
    Health Care

    Alnylam Pharmaceuticals joins Alliance for Genomic Discovery, expanding diverse clinical genomic dataset to drive precision medicine

    Alnylam, a leader in RNA interference (RNAi) therapeutics, will utilize the AGD dataset to inform development of 'gene silencing' medicines Members leverage AI-powered dataset to accelerate pharma R&D, and ensure that disease-impacting discoveries benefit all people SAN DIEGO, Sept. 18, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN), and Nashville Biosciences, LLC (NashBio), today announced Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) (Alnylam) as a member of the Alliance for Genomic Discovery (AGD). Alnylam, a pioneer in RNA interference (RNAi) therapeutics, will utilize the AGD clinical genomic database to derive real-world insights and accelerate drug target discovery.

    9/18/25 9:15:00 AM ET
    $ALNY
    $ILMN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities

    BioStem Technologies Appoints Brandon Poe as Chief Financial Officer

    POMPANO BEACH, Fla., Aug. 14, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. ("BioStem" or the "Company") (OTC:BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today announced the appointment of Brandon Poe as its Chief Financial Officer (CFO). Mr. Poe has served on BioStem's Board of Directors since 2022. Michael Fortunato, the Company's prior CFO, has assumed the role of Chief Accounting Officer. "I'm excited to welcome Brandon as CFO during this pivotal period of growth and innovation for BioStem," said Jason Matuszewski, Chairman and CEO. "Brandon brings proven financial leader

    8/14/25 4:01:44 PM ET
    $ILMN
    Medical Specialities
    Health Care